Compare YHGJ & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHGJ | ALZN |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | 2006 | 2021 |
| Metric | YHGJ | ALZN |
|---|---|---|
| Price | $2.88 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 3.6K | ★ 83.8K |
| Earning Date | 05-19-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,705,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $0.50 | $0.84 |
| 52 Week High | $10.29 | $2.68 |
| Indicator | YHGJ | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 65.28 |
| Support Level | $2.61 | $1.41 |
| Resistance Level | $3.11 | $2.25 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 0.00 | 90.32 |
Yunhong Green CTI Ltd develops, produces, distributes, and sells consumer products in the United States and several other countries, and manufactures film products for commercial and industrial use in the United States. The Company focuses on flexible film technologies and has developed products utilizing flexible films, including novelty balloons, pouches, and films for packaging applications. Its principal product lines include foil and latex balloons and related gift items, and flexible films for food and other packaging uses. It also assembles balloon-inspired gift items, including small gift bouquets with ribbons and/or a foil balloon, and holds patents related to flexible films, including films, zipper closures, valves, and other features.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.